Abstracts tagged "Pediatric rheumatology"

Abstract Number: 1673 • ACR Convergence 2020
Principles of Pediatric Lupus Nephritis in a Contemporary Multi-Center Cohort
Kathleen Vazzana¹, Ankana Daga², Beatrice Goilav³, Ekemini Ogbu⁴, Daryl Okamura⁵, Catherine Park⁶, Rebecca Sadun⁷, Emily Smitherman⁸, Brian Stotter⁹, Scott Wenderfer¹⁰ and Laura Lewandowski¹¹, ¹National Institute of Health/Children's National Hospital, Washington, DC, ²Harvard, Boston, MA, ³The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Seattle's Children's, Seattle, WA, ⁶Emory University, Atlanta, GA, ⁷Duke University, Durham, NC, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Washington University School of Medicine, St. Louis, MO, ¹⁰Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, ¹¹NIAMS, NIH, Rockville, MD
Background/Purpose: Lupus nephritis (LN) is a well-established and life-threatening manifestation of systemic lupus erythematosus (SLE) that is more common in children than adults. The demographics…
Abstract Number: 1692 • ACR Convergence 2020
Poor Physical Activity Levels and Cardiorespiratory Fitness Among Patients with Childhood-Onset Takayasu Arteritis in Remission
Camilla Astley¹, Saulo Gil², Gleice Clemente³, Maria Teresa Terreri⁴, Lucia Campos⁵, Nadia Aikawa⁵, Ana Lucia de-Sá Pinto², Rosa Pereira⁵, Hamilton Roschel² and Bruno Gualano², ¹University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²University of Sao Paulo, Sao paulo, Brazil, ³Federal University of Sao Paulo, Sao Paulo, Brazil, ⁴Federal University of São Paulo, São Paulo, Brazil, ⁵Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Childhood-onset Takayasu Arteritis (c-TA) is a rare, granulomatous, chronic large-vessel vasculitis that involves mostly the aorta and its major branches with a high mortality…
Abstract Number: 0608 • ACR Convergence 2020
Patient and Parent Perspectives in a Academic Pediatric Rheumatology Transition Clinic
Rebecca Overbury¹, Tracy Frech², John Bohnsack³, CJ Inman¹, Sara Stern¹, Karen James¹, Erin Treemarcki⁴ and Aimee Hersh⁴, ¹University of Utah and Primary Children's Hospital, Salt Lake City, UT, ²University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ³University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁴University of Utah and Primary Children's Hospital, Salt Lake City
Background/Purpose: In November 2018 we initiated a transition clinic called ACCORD (Adult Center for Childhood Onset Rheumatic Disease). Our unique structure integrates an adult rheumatologist…
Abstract Number: 0734 • ACR Convergence 2020
Differences and Similarities Between down Syndrome-associated Arthritis and Juvenile Idiopathic Arthritis in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Jordan Jones¹, Chelsey Smith², Daniel J Lovell³ and Mara Becker⁴, ¹Children's Mercy Kansas City, Kansas City, MO, ²Children's Mercy Kansas City, Holden, MO, ³PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Duke University School of Medicine, Durham, NC
Background/Purpose: Down syndrome-associated arthritis (DA) is under-recognized with delay in diagnosis (1). The majority of those with DA present with polyarticular, rheumatoid factor (RF) and…
Abstract Number: 1166 • ACR Convergence 2020
Use of Rituximab to Treat COPA Syndrome: A Multi-Institutional Cohort
Leigh Stubbs¹, Isabella Osuna², Tarin Bigley³, Michal Cidon⁴, Kristen Mengwasser⁵, Simon Helfgott⁶, Marietta DeGuzman⁷, Manuel Silva-Carmona⁸ and Tiphanie Vogel⁹, ¹Baylor College of Medicine, Houston, TX, ²Department of Pediatrics, Division of Rheumatology, Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas, USA, Houston, TX, ³Washington University in St. Louis, Saint Louis, MO, ⁴CHLA, Los Angeles, CA, ⁵Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts, USA, Boston, MA, ⁶BWH- HMS, Boston, MA, ⁷Baylor College of Medicine, Houston, ⁸Department of Pediatrics, Division of Pulmonology Medicine, Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas, USA, Houston, TX, ⁹Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Coatomer protein complex subunit α (COPA) syndrome is a rare genetic multisystem autoimmune disorder inherited in an autosomal dominant manner. Onset typically occurs in…
Abstract Number: 1495 • ACR Convergence 2020
Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study
Hermine I Brunner¹, Jonathan Akikusa², Eslam Al-Abadi², John Bohnsack³, Alina Lucica Boteanu², Gaelle Chedeville⁴, Ruben Cuttica², Wendy De La Pena⁴, Lawrence Jung⁴, Ozgur Kasapcopur², Katarzyna Kobusinska², Grant Schulert¹, Claudia Neiva², Rafael Rivas-Chacon⁴, Juan Cruz Rizo Rodriguez², Monica Vazquez-Del Mercado², Linda Wagner-Weiner⁴, Jennifer E Weiss¹, Carine Wouters², Ricardo M Suehiro⁵, Holly Posner⁶, Ann Wouters⁶, Keith S Kanik⁷, Zhen Luo⁸, Alberto Martini², Daniel J Lovell¹ and Nicolino Ruperto², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁴PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Shanghai, China (People's Republic)
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. We report the safety, tolerability, and efficacy of tofacitinib in patients (pts)…
Abstract Number: 1674 • ACR Convergence 2020
Pediatric and Adolescent One Year Protocol Kidney Biopsies Should Be Performed, Even in Patients with Complete Remission of Their Lupus Nephritis
Peter Yorgin¹, Suhas Radhakrishna¹, Caitlin Carter¹, Johanna Chang¹, Katayoon Shayan¹, Lieuko Nguyen¹, Peter Chiraseveenuprapund¹ and Robert Sheets², ¹UCSD/Rady Children's Hospital, San Diego, CA, ²University of California San Diego, San Diego, CA
Background/Purpose: The value of one-year protocol kidney biopsies in children who have proliferative lupus nephritis (LN) is unclear, particularly in patients who meet CARRA criteria…
Abstract Number: 1693 • ACR Convergence 2020
Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease
Alexis Wilsey¹, Laura Cannon², Stephanie Johannes² and Heather Van Mater², ¹Duke University School of Medicine, Durham, ²Duke University, Durham, NC
Background/Purpose: Rituximab is standard therapy for autoimmune brain disease (ABD) including autoimmune encephalitis (AE) and Neuromyelitis Optica Spectrum Disease (NMOSD). Recommendations for continuing concurrent intravenous…
Abstract Number: 0634 • ACR Convergence 2020
Influenza Knowledge and Barriers to Vaccination in Immunosuppressed Patients in the Pediatric Rheumatology Clinic
Julia Harris¹, Maria Ibarra², Michael Holland², Kelly Jensen³, Emily Fox², Jordan Jones², Leslie Favier⁴, Ashley Sherman², Chelsey Smith⁵ and Ashley Cooper², ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Kansas City, Kansas City, MO, ³Children's Mercy Kansas City, Kansas City, ⁴Children's Mercy Kansas City, Leawood, KS, ⁵Children's Mercy Kansas City, Holden, MO
Background/Purpose: Many pediatric rheumatology patients are at increased risk of influenza due to immunosuppressive medication use. Annual influenza vaccination is recommended for all children by…
Abstract Number: 0735 • ACR Convergence 2020
Paediatric Sarcoidosis: Phenotype of a Retrospective Cohort of Biopsy-proven Patients
Kerstin Nott¹, Veronica Nott² and Sandrine Compeyrot-Lacassagne¹, ¹Great Ormond Street Hospital for Children, London, United Kingdom, ²Imperial College, ANDOVER, United Kingdom
Background/Purpose: Paediatric sarcoidosis is a multisystemic inflammatory condition characterised by the formation of non-caseating granulomata that may lead to end-organ damage. Diagnosis is challenging as…
Abstract Number: 1167 • ACR Convergence 2020
Capturing the Range of Disease Involvement in Localized Scleroderma: The Total Morbidity Score
Suzanne Li¹, Aashka Patel¹, Elena Pope², Thomas Mason³, Vidya Sivaraman⁴, Fatma Dedeoglu⁵, Kathryn Torok⁶, Katie Stewart⁷, Gloria Higgins⁸, C. Egla Rabinovich⁹, Robert Fuhlbrigge¹⁰, Maria Ibarra¹¹, Sandy Hong¹², Polly Ferguson¹³, Mara Becker¹⁴, Brian Feldman¹⁵, Ronald Laxer¹⁵ and CARRA Investigators¹⁶, ¹Hackensack University Medical Center, Hackensack, ²Hospital For Sick Kids, Toronto, ON, Canada, ³Mayo Clinic, Rochester, MN, ⁴Nationwide Children's Hospital, Bexley, OH, ⁵Boston Children's Hospital, Boston, MA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷UT Southwestern, Dallas, TX, ⁸Nationwide Childrens Hospital/ The Ohio State University, Columbus, OH, ⁹Duke University Hospital, Durham, NC, ¹⁰University of Colorado, Denver, CO, ¹¹Children's Mercy Kansas City, Kansas City, MO, ¹²University of Iowa Stead Family Children's Hospital, Iowa City, IA, ¹³University of Iowa Carver College of Medicine, Iowa City, IA, ¹⁴Duke University School of Medicine, Durham, NC, ¹⁵The Hospital for Sick Children, Toronto, ON, Canada, ¹⁶CARRA, Durham
Background/Purpose: Localized scleroderma (LS) is a chronic inflammatory and fibrosing disease that causes both cutaneous and extracutaneous (EC) damage. EC involvement (ECI) is common in juvenile…
Abstract Number: 1509 • ACR Convergence 2020
Leukocyte Telomere Length and Childhood Onset of Systemic Lupus Erythematosus in the Black Women’s Experiences Living with Lupus (BeWELL) Study
John Bridges¹, Kara Chung², Connor Martz², Emily Smitherman¹, Cristina Drenkard³, S. Sam Lim⁴ and David Chae², ¹University of Alabama at Birmingham, Birmingham, AL, ²Auburn University, Auburn, AL, ³Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA, ⁴Emory University, Atlanta, GA
Background/Purpose: Childhood-onset SLE is generally more aggressive than adult-onset SLE. Leukocyte telomere length (LTL) has been posited to reflect immune system aging. Short LTL in…
Abstract Number: 1676 • ACR Convergence 2020
Neuropsychiatric Involvement in Juvenile-onset Systemic Lupus Erythematosus (JSLE): Data from the UK JSLE Cohort Study
Teresa Giani¹, Eve Smith², Rolando Cimaz³, Michael Beresford⁴ and Christian Hedrich², ¹AOU Meyer, Florence, Italy, ²University of Liverpool, Liverpool, United Kingdom, ³ASST Gaetano Pini-CTO Institute and Università degli Studi di Milano, Milan, Italy, Milan, Italy, ⁴Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is a rare autoimmune/inflammatory disease, accounting for up to 20% of SLE cases. Though clinically similar to adult-onset disease,…
Abstract Number: 1694 • ACR Convergence 2020
Risk Factors Associated with Pneumocystis Jirovecii Pneumonia in Juvenile Myositis in North America
Sara Sabbagh¹, Jessica Neely², Albert Chow³, Marietta DeGuzman⁴, Jamie Lai⁵, Svetlana Lvovich⁶, Tara McGrath⁷, Maria Pereira⁸, Iago Pinal-Fernandez⁹, Jordan Roberts¹⁰, Kelly Rouster-Stevens¹¹, Heinrike Schmeling¹², Anjali Sura¹³, Gabriel Tarshish¹⁴, Lori Tucker¹⁵, Lisa G. Rider¹⁶ and Susan Kim¹⁷, ¹Medical College of Wisconsin, Fox Point, WI, ²UCSF, San Francisco, CA, ³Loma Linda University, San Bernardino, CA, ⁴Baylor College of Medicine, Houston, ⁵University of Colorado, The Woodlands, TX, ⁶St Christopher's Hospital for Children, Philadelphia, PA, ⁷University of British Columbia, Vancouver, BC, Canada, ⁸Baylor College of Medicine, Houston, TX, ⁹National Institutes of Health, Bethesda, MD, ¹⁰Boston Children's Hospital, Boston, MA, ¹¹Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹²University of Calgary, Calgary, AB, Canada, ¹³Upstate University Hospital, Syracuse, NY, ¹⁴Children's Hospital at Montefiore, New York, NY, ¹⁵BC Children's Hospital, Vancouver, BC, Canada, ¹⁶Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, ¹⁷UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Pneumocystis jirovecii pneumonia (PJP) is associated with significant morbidity and mortality in adult myositis patients; however, few studies have examined PJP in juvenile myositis…
Abstract Number: 0712 • ACR Convergence 2020
Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis
Ilaria Maccora¹, Gabriele Simonini², Alessandra Bettiol³, Ilaria Pagnini⁴, Niccolò Lombardi⁵, Valerio Maniscalco⁶, Giada Crescioli⁵, Edoardo Marrani⁷, Roberto Bonaiuti⁵, Maria Vincenza Mastrolia⁸, Claudia Ravaldi⁹ and Alfredo Vannacci⁵, ¹Paediatric Rheumatology Unit, Anna Meyer Children's University Hospital, School of Human Health Science, Florence, Italy, Florence, Italy, ²Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy, ³2. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy, Florence, ⁴1. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy, florence, Italy, ⁵2. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy., Florence, Italy, ⁶1. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy., florence, Italy, ⁷University of Florence, Firenze, Italy, ⁸Rheumatology Unit, Meyer Children's University Hospital, Firenze, Italy, Florence, Toscana, Italy, ⁹3. Department of Health Sciences, University of Florence, Florence, Italy., Florence, Italy
Background/Purpose: Limited data about the use of biosimilar are available in children with Juvenile Idiopathic Arthritis (JIA). To evaluate the long-term efficacy and safety of switching…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].